These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34905263)

  • 1. Paradoxical psoriatic arthritis in a patient with psoriasis treated with guselkumab.
    Carriero A; Lubrano E; Picerno V; Padula AA; D'Angelo S
    Clin Exp Dermatol; 2022 Apr; 47(4):783-785. PubMed ID: 34905263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment on: 'Paradoxical psoriatic arthritis in a patient with psoriasis treated with guselkumab'.
    Akturk S; Altunisik N; Buyukavci R; Turkmen D
    Clin Exp Dermatol; 2022 Jul; 47(7):1363-1364. PubMed ID: 35266569
    [No Abstract]   [Full Text] [Related]  

  • 3. A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab.
    Megna M; Marano L; Camela E; Potestio L; Fabbrocini G; Scalvenzi M; Guerrasio G
    Dermatol Ther; 2022 Oct; 35(10):e15766. PubMed ID: 35959513
    [No Abstract]   [Full Text] [Related]  

  • 4. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
    Boehncke WH; Brembilla NC; Nissen MJ
    Expert Rev Clin Immunol; 2021 Jan; 17(1):5-13. PubMed ID: 33251833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
    Helliwell PS; Deodhar A; Gottlieb AB; Boehncke WH; Xu XL; Xu S; Wang Y; Hsia EC; Gladman DD; Ritchlin CT
    Arthritis Care Res (Hoboken); 2020 Nov; 72(11):1579-1588. PubMed ID: 31421033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixekizumab-associated disseminated tinea corporis in a patient with psoriatic arthritis and plaque psoriasis.
    Naraghi K; Shams K; Marzo-Ortega H
    Rheumatology (Oxford); 2023 Jun; 62(6):e209-e210. PubMed ID: 36342185
    [No Abstract]   [Full Text] [Related]  

  • 8. Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.
    Rahman P; Ritchlin CT; Helliwell PS; Boehncke WH; Mease PJ; Gottlieb AB; Kafka S; Kollmeier AP; Hsia EC; Xu XL; Shawi M; Sheng S; Agarwal P; Zhou B; Ramachandran P; Zhuang Y; McInnes IB
    J Rheumatol; 2021 Dec; 48(12):1815-1823. PubMed ID: 33934076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
    Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.
    Puig L
    Expert Rev Clin Immunol; 2019 Jun; 15(6):589-597. PubMed ID: 30920855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
    Mease PJ; Rahman P; Gottlieb AB; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; van der Heijde D; McInnes IB;
    Lancet; 2020 Apr; 395(10230):1126-1136. PubMed ID: 32178766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
    Deodhar A; Helliwell PS; Boehncke WH; Kollmeier AP; Hsia EC; Subramanian RA; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; Ritchlin CT;
    Lancet; 2020 Apr; 395(10230):1115-1125. PubMed ID: 32178765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab.
    Rodríguez-Cuadrado FJ; Roustan-Gullón G; Suárez-Massa D; Hospital-Gil M
    An Bras Dermatol; 2024; 99(5):783-785. PubMed ID: 38876967
    [No Abstract]   [Full Text] [Related]  

  • 14. Ustekinumab for psoriatic arthritis.
    Cuchacovich RS; Espinoza LR
    Lancet; 2009 Feb; 373(9664):605-6. PubMed ID: 19217153
    [No Abstract]   [Full Text] [Related]  

  • 15. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.
    Mrowietz U; Riedl E; Winkler S; Xu W; Patel H; Agada N; Lebwohl MG
    J Am Acad Dermatol; 2020 Nov; 83(5):1436-1439. PubMed ID: 32526319
    [No Abstract]   [Full Text] [Related]  

  • 16. Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis.
    Chen Y; Miao X; Hsu CH; Zhuang Y; Kollmeier A; Xu Z; Zhou H; Sharma A
    Clin Transl Sci; 2022 Mar; 15(3):749-760. PubMed ID: 34854241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixekizumab in the treatment of psoriatic arthritis.
    Lespessailles E; Toumi H
    Immunotherapy; 2021 Jan; 13(1):19-33. PubMed ID: 33167745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of ixekizumab in an HIV-positive patient with psoriatic arthritis.
    Qian F; Yan Y; Huang J; Xu W; Zhu Y; Liu J; Wu X; Chen F
    Int J STD AIDS; 2022 Apr; 33(5):519-521. PubMed ID: 35220812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of guselkumab in two psoriatic patients with hepatitis B and C virus infection.
    Messina F; Peccerillo F; Odorici G; Conti A; Piaserico S
    Dermatol Ther; 2022 Mar; 35(3):e15281. PubMed ID: 34931414
    [No Abstract]   [Full Text] [Related]  

  • 20. Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
    Reich K; Baraliakos X; Coates LC; Elewski B; Bao W; Kasparek T; Gaillez C; Pournara E; Aassi M; Perella C; Gottlieb AB
    Br J Dermatol; 2022 Sep; 187(3):438-441. PubMed ID: 35257363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.